TRAVAUX SCIENTIFIQUES

Poster - Ultrasonography versus Radiography post CT guided biopsy, American Thoracic Society International Conference 2020

Activité d'essais cliniques (Investigateur Principal ) - CHU Bordeaux

A Phase 3, Randomized, Double-blind, Placebo- and Active-ComparatorControlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

Activité d'essais cliniques (Co-Investigateur) - CHU Bordeaux

•MARIPOSA - A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PAPILLON - A Randomized, Open-label Phase 3 Study of Combination Amivantamab andCarboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

GFPC06-2018 - IMMUNOADDICT : A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after Targeted therapies

D910MC00001 - MERMAID 2 : A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2)

MS2000950031 - INSIGHT 2 : A phase 2, two arms study to investigate TEPOTINIB combined with osimertinib in MET amplified, advanced or metastatic NSCLC harboring activating EGFR mutations and having required resistance to prior osimertinib therapy

CACZ885T2301 - CANOPI : A phase III, multicenter, randomized, double blind, placebocontrolled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)

IFCT-2003 - ALBATROS : phase II mono-bras, multicentrique évaluant l'efficacité et la tolérance du lorlatinib en monothérapie après échec en 1ère ligne de traitement d'un inhibiteur de tyrosine kinase chez des patients présentant un CBNPC de stade avancé ROS1-positif.

20190288 - CODEBREAK 201 : Phase 2 évaluant le sotorasib en première ligne des CBNPC KRAS G12C PDL1<1% et/ou co-mutation STK11

ACT 16146 - CARMEN : Randomized, open-label, Phase 2 study of SAR408701 combined with pembrolizumab and pembrolizumab alone in patients with CEACAM5 and PD-L1 positive advanced/metastatic non-squamous non-small-cell lung cancer (NSQ NSCLC)

CA2097HX - LIST : A Multi-Center, Longitudinal, Prospective, Observational, Multi-Cohort Study of Patients with Advanced Non-Small Cell Lung Cancer treated with nivolumab in France after at leastone prior chemotherapy-based treatment (LIST, Lung Initiative on Sequence Therapy)

GSK 213403 - PERLA : A randomized, phase 2, double-blind study to evaluate the efficacy of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic non-squamous non-small cell lung cancer

EVOKE 2 - Open-Label, Global, Multicenter, Randomized, Phase 3 Study of

Sacituzumab Govitecan Versus Docetaxel in Patients With

Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

With Progression on or After Platinum-Based Chemotherapy and

Anti-PD-1/PD-L1 Immunotherapy

LATIFY -  A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY

ADAPTABLE A non-comparative randomized phase II trial evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced non-squamous NSCLC progressing after immunotherapy and chemotherapy

ABBVIE TELIMET M18-868 - A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR WildtypeLocally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

 IFCT Master protocol ALK A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non-small cell lung cancer

GFPC 01-2020 PERSEE - A randomized, open-label, controlled phase III trial comparing the pembrolizumab-platinum-based chemotherapy combination with pembrolizumab monotherapy in first-line treatment of non-small-cell lung cancer (NSCLC) patients with PD-L1 expression ≥50% on tumor cells